Cancer researcher and break-through drug developer Geoffrey Weiss recently was appointed the University Medical Center's newest chief of hematology-oncology and deputy director of the cancer center.
Weiss previously conducted research at the University of Texas, where he developed the cancer fighting drug interleukin-2, which was approved by the Food and Drug Administration in 1993.
Interleukin-2, used primarily to combat kidney and skin cancer, results in remission among 20 percent of the patients who use it.
Weiss told the Daily Progress that in his new role at the University, he plans to develop targeted therapies, drugs that work to destroy altered cancer-causing cell proteins.
Weiss said he also plans to hire nine new researchers within the next five years and earn the University's Medical Center a top-10 ranking for cancer research.
Read More
Former UJC Chair Allison McVey reflects on term with 31 cases adjudicated
By Melody Yuan | 12 hours agoDuring her term, 31 cases were adjudicated, and she also worked to establish the policies and projects subcommittee and engage alumni.
UDems, state legislators urge students to support redistricting at press conference
By Luca Bailey | 12 hours agoApril’s ballot question asks voters whether they support amending the Commonwealth’s Constitution to temporarily bypass the independent Virginia Redistricting Commission.
Even after federal anti-DEI guidance was struck down, U.Va. says its changes will remain
By Brendon Bordwine | 21 hours agoThe Board of Visitors’ March 7, 2025 resolution dissolving the Office of Diversity, Equity, Inclusion and Community Partnerships and directing a broader compliance review of University programs remains in place and continues to guide the University’s DEI policies.
